Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis.

Bejar J, Kessler O, Sabag AD, Sabo E, Itzhak OB, Neufeld G, Vadasz Z.

Front Immunol. 2018 Apr 4;9:634. doi: 10.3389/fimmu.2018.00634. eCollection 2018.

2.

Complexes of plexin-A4 and plexin-D1 convey semaphorin-3C signals to induce cytoskeletal collapse in the absence of neuropilins.

Smolkin T, Nir-Zvi I, Duvshani N, Mumblat Y, Kessler O, Neufeld G.

J Cell Sci. 2018 May 4;131(9). pii: jcs208298. doi: 10.1242/jcs.208298.

PMID:
29661844
3.

A three-gene signature from protein-protein interaction network of LOXL2- and actin-related proteins for esophageal squamous cell carcinoma prognosis.

Zhan XH, Jiao JW, Zhang HF, Li CQ, Zhao JM, Liao LD, Wu JY, Wu BL, Wu ZY, Wang SH, Du ZP, Shen JH, Zou HY, Neufeld G, Xu LY, Li EM.

Cancer Med. 2017 Jul;6(7):1707-1719. doi: 10.1002/cam4.1096. Epub 2017 May 29.

4.

A Sema3C Mutant Resistant to Cleavage by Furin (FR-Sema3C) Inhibits Choroidal Neovascularization.

Toledano S, Lu H, Palacio A, Ziv K, Kessler O, Schaal S, Neufeld G, Barak Y.

PLoS One. 2016 Dec 30;11(12):e0168122. doi: 10.1371/journal.pone.0168122. eCollection 2016.

5.

The semaphorins and their receptors as modulators of tumor progression.

Neufeld G, Mumblat Y, Smolkin T, Toledano S, Nir-Zvi I, Ziv K, Kessler O.

Drug Resist Updat. 2016 Nov;29:1-12. doi: 10.1016/j.drup.2016.08.001. Epub 2016 Aug 28. Review.

PMID:
27912840
6.

A SEMA3E mutant resistant to cleavage by furins (UNCL-SEMA3E) inhibits choroidal neovascularization.

Toledano S, Lu H, Palacio A, Kigel B, Kessler O, Allon G, Barak Y, Neufeld G, Schaal S.

Exp Eye Res. 2016 Dec;153:186-194. doi: 10.1016/j.exer.2016.10.004. Epub 2016 Oct 7.

PMID:
27725196
7.

Dormant tumor cells expressing LOXL2 acquire a stem-like phenotype mediating their transition to proliferative growth.

Weidenfeld K, Schif-Zuck S, Abu-Tayeh H, Kang K, Kessler O, Weissmann M, Neufeld G, Barkan D.

Oncotarget. 2016 Nov 1;7(44):71362-71377. doi: 10.18632/oncotarget.12109.

8.

The role of the semaphorins in cancer.

Neufeld G, Mumblat Y, Smolkin T, Toledano S, Nir-Zvi I, Ziv K, Kessler O.

Cell Adh Migr. 2016 Nov;10(6):652-674. Epub 2016 Aug 17. Review.

9.

Heparanase 2 Attenuates Head and Neck Tumor Vascularity and Growth.

Gross-Cohen M, Feld S, Doweck I, Neufeld G, Hasson P, Arvatz G, Barash U, Naroditsky I, Ilan N, Vlodavsky I.

Cancer Res. 2016 May 1;76(9):2791-801. doi: 10.1158/0008-5472.CAN-15-1975. Epub 2016 Mar 24.

10.

Localized LoxL3-Dependent Fibronectin Oxidation Regulates Myofiber Stretch and Integrin-Mediated Adhesion.

Kraft-Sheleg O, Zaffryar-Eilot S, Genin O, Yaseen W, Soueid-Baumgarten S, Kessler O, Smolkin T, Akiri G, Neufeld G, Cinnamon Y, Hasson P.

Dev Cell. 2016 Mar 7;36(5):550-61. doi: 10.1016/j.devcel.2016.02.009.

11.

Electron spin resonance microscopic imaging of oxygen concentration in cancer spheroids.

Hashem M, Weiler-Sagie M, Kuppusamy P, Neufeld G, Neeman M, Blank A.

J Magn Reson. 2015 Jul;256:77-85. doi: 10.1016/j.jmr.2015.04.012. Epub 2015 May 13.

PMID:
26022394
12.

Full-Length Semaphorin-3C Is an Inhibitor of Tumor Lymphangiogenesis and Metastasis.

Mumblat Y, Kessler O, Ilan N, Neufeld G.

Cancer Res. 2015 Jun 1;75(11):2177-86. doi: 10.1158/0008-5472.CAN-14-2464. Epub 2015 Mar 25.

13.

The role of the plexin-A2 receptor in Sema3A and Sema3B signal transduction.

Sabag AD, Smolkin T, Mumblat Y, Ueffing M, Kessler O, Gloeckner CJ, Neufeld G.

J Cell Sci. 2014 Dec 15;127(Pt 24):5240-52. doi: 10.1242/jcs.155960. Epub 2014 Oct 21.

14.

Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.

Zaffryar-Eilot S, Marshall D, Voloshin T, Bar-Zion A, Spangler R, Kessler O, Ghermazien H, Brekhman V, Suss-Toby E, Adam D, Shaked Y, Smith V, Neufeld G.

Carcinogenesis. 2013 Oct;34(10):2370-9. doi: 10.1093/carcin/bgt241. Epub 2013 Jul 4.

PMID:
23828904
15.

The chemorepulsive axon guidance protein semaphorin3A is a constituent of perineuronal nets in the adult rodent brain.

Vo T, Carulli D, Ehlert EM, Kwok JC, Dick G, Mecollari V, Moloney EB, Neufeld G, de Winter F, Fawcett JW, Verhaagen J.

Mol Cell Neurosci. 2013 Sep;56:186-200. doi: 10.1016/j.mcn.2013.04.009. Epub 2013 May 9.

PMID:
23665579
16.

The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.

Tadmor T, Bejar J, Attias D, Mischenko E, Sabo E, Neufeld G, Vadasz Z.

Am J Hematol. 2013 May;88(5):355-8. doi: 10.1002/ajh.23409. Epub 2013 Mar 12.

17.

Neuropilin-1-dependent regulation of EGF-receptor signaling.

Rizzolio S, Rabinowicz N, Rainero E, Lanzetti L, Serini G, Norman J, Neufeld G, Tamagnone L.

Cancer Res. 2012 Nov 15;72(22):5801-11. doi: 10.1158/0008-5472.CAN-12-0995. Epub 2012 Sep 17.

18.

Semaphorin-3D and semaphorin-3E inhibit the development of tumors from glioblastoma cells implanted in the cortex of the brain.

Sabag AD, Bode J, Fink D, Kigel B, Kugler W, Neufeld G.

PLoS One. 2012;7(8):e42912. doi: 10.1371/journal.pone.0042912. Epub 2012 Aug 24.

19.

Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus.

Vadasz Z, Haj T, Halasz K, Rosner I, Slobodin G, Attias D, Kessel A, Kessler O, Neufeld G, Toubi E.

Arthritis Res Ther. 2012 Jun 14;14(3):R146. doi: 10.1186/ar3881.

20.

Semaphorins in angiogenesis and tumor progression.

Neufeld G, Sabag AD, Rabinovicz N, Kessler O.

Cold Spring Harb Perspect Med. 2012 Jan;2(1):a006718. doi: 10.1101/cshperspect.a006718. Review.

21.

Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform.

Casazza A, Kigel B, Maione F, Capparuccia L, Kessler O, Giraudo E, Mazzone M, Neufeld G, Tamagnone L.

EMBO Mol Med. 2012 Mar;4(3):234-50. doi: 10.1002/emmm.201100205. Epub 2012 Jan 13.

22.

The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation.

Lugassy J, Zaffryar-Eilot S, Soueid S, Mordoviz A, Smith V, Kessler O, Neufeld G.

J Biol Chem. 2012 Jan 27;287(5):3541-9. doi: 10.1074/jbc.M111.261016. Epub 2011 Dec 8.

23.

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y.

Oncogene. 2012 Aug 2;31(31):3569-83. doi: 10.1038/onc.2011.547. Epub 2011 Dec 5.

24.

Integration of repulsive guidance cues generates avascular zones that shape mammalian blood vessels.

Meadows SM, Fletcher PJ, Moran C, Xu K, Neufeld G, Chauvet S, Mann F, Krieg PA, Cleaver O.

Circ Res. 2012 Jan 6;110(1):34-46. doi: 10.1161/CIRCRESAHA.111.249847. Epub 2011 Nov 10.

25.

Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling.

Kigel B, Rabinowicz N, Varshavsky A, Kessler O, Neufeld G.

Blood. 2011 Oct 13;118(15):4285-96. doi: 10.1182/blood-2011-03-341388. Epub 2011 Aug 10.

26.

Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.

Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V.

Nat Med. 2010 Sep;16(9):1009-17. doi: 10.1038/nm.2208. Epub 2010 Sep 5.

PMID:
20818376
27.

Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2.

Brekhman V, Lugassie J, Zaffryar-Eilot S, Sabo E, Kessler O, Smith V, Golding H, Neufeld G.

FASEB J. 2011 Jan;25(1):55-65. doi: 10.1096/fj.10-162677. Epub 2010 Aug 27.

PMID:
20802105
28.

Sema-3A indirectly disrupts the regeneration process of goldfish optic nerve after controlled injury.

Rosenzweig S, Raz-Prag D, Nitzan A, Galron R, Paz M, Jeserich G, Neufeld G, Barzilai A, Solomon AS.

Graefes Arch Clin Exp Ophthalmol. 2010 Oct;248(10):1423-35. doi: 10.1007/s00417-010-1377-y. Epub 2010 May 7.

PMID:
20449604
29.

A novel asymmetric 3D in-vitro assay for the study of tumor cell invasion.

Brekhman V, Neufeld G.

BMC Cancer. 2009 Nov 30;9:415. doi: 10.1186/1471-2407-9-415.

30.

Cardiac repolarization indices in epilepsy patients.

Neufeld G, Lazar JM, Chari G, Kamran H, Akajagbor E, Salciccioli L, Kassotis J, Stewart M.

Cardiology. 2009;114(4):255-60. doi: 10.1159/000233236. Epub 2009 Aug 12.

PMID:
19672064
31.

Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells.

Kigel B, Varshavsky A, Kessler O, Neufeld G.

PLoS One. 2008 Sep 26;3(9):e3287. doi: 10.1371/journal.pone.0003287.

32.

Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases.

Varshavsky A, Kessler O, Abramovitch S, Kigel B, Zaffryar S, Akiri G, Neufeld G.

Cancer Res. 2008 Sep 1;68(17):6922-31. doi: 10.1158/0008-5472.CAN-07-5408.

33.

Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1.

Prahst C, Héroult M, Lanahan AA, Uziel N, Kessler O, Shraga-Heled N, Simons M, Neufeld G, Augustin HG.

J Biol Chem. 2008 Sep 12;283(37):25110-4. doi: 10.1074/jbc.C800137200. Epub 2008 Jul 15.

34.

The semaphorins: versatile regulators of tumour progression and tumour angiogenesis.

Neufeld G, Kessler O.

Nat Rev Cancer. 2008 Aug;8(8):632-45. doi: 10.1038/nrc2404. Epub 2008 Jun 26. Review.

PMID:
18580951
35.

Semaphorin signaling in vascular and tumor biology.

Neufeld G, Lange T, Varshavsky A, Kessler O.

Adv Exp Med Biol. 2007;600:118-31. Review.

PMID:
17607951
36.

Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis.

Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G.

J Biol Chem. 2007 Sep 7;282(36):26294-305. Epub 2007 Jun 14.

37.

Neuropilin-1 and neuropilin-2 enhance VEGF121 stimulated signal transduction by the VEGFR-2 receptor.

Shraga-Heled N, Kessler O, Prahst C, Kroll J, Augustin H, Neufeld G.

FASEB J. 2007 Mar;21(3):915-26. Epub 2006 Dec 21.

PMID:
17185751
38.

Pro-angiogenic cytokines and their role in tumor angiogenesis.

Neufeld G, Kessler O.

Cancer Metastasis Rev. 2006 Sep;25(3):373-85. Review.

PMID:
17006765
39.

Functional interaction of VEGF-C and VEGF-D with neuropilin receptors.

Kärpänen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, Tamagnone L, Alitalo K.

FASEB J. 2006 Jul;20(9):1462-72.

PMID:
16816121
40.

Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration.

Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P, Mandron M, Herault JP, Neufeld G, Savi P, Herbert JM, Bono F.

Blood. 2006 Aug 15;108(4):1243-50. Epub 2006 Apr 18.

41.

The neuropilins and their role in tumorigenesis and tumor progression.

Guttmann-Raviv N, Kessler O, Shraga-Heled N, Lange T, Herzog Y, Neufeld G.

Cancer Lett. 2006 Jan 8;231(1):1-11. Review.

PMID:
16356825
42.

Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.

Vadasz Z, Kessler O, Akiri G, Gengrinovitch S, Kagan HM, Baruch Y, Izhak OB, Neufeld G.

J Hepatol. 2005 Sep;43(3):499-507.

PMID:
16023247
43.

HVEGF165 increases survival of transplanted hepatocytes within portal radicles: suggested mechanism for early cell engraftment.

Shani-Peretz H, Tsiperson V, Shoshani G, Veitzman E, Neufeld G, Baruch Y.

Cell Transplant. 2005;14(1):49-57.

PMID:
15789662
44.

Segregation of arterial and venous markers in subpopulations of blood islands before vessel formation.

Herzog Y, Guttmann-Raviv N, Neufeld G.

Dev Dyn. 2005 Apr;232(4):1047-55.

45.

Semaphorins in cancer.

Neufeld G, Shraga-Heled N, Lange T, Guttmann-Raviv N, Herzog Y, Kessler O.

Front Biosci. 2005 Jan 1;10:751-60. Print 2005 Jan 1. Review.

PMID:
15569615
46.

Semaphorin-3F is an inhibitor of tumor angiogenesis.

Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, Machluf M, Neufeld G.

Cancer Res. 2004 Feb 1;64(3):1008-15.

47.

Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells.

Fukahi K, Fukasawa M, Neufeld G, Itakura J, Korc M.

Clin Cancer Res. 2004 Jan 15;10(2):581-90.

48.

Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres.

Perets A, Baruch Y, Weisbuch F, Shoshany G, Neufeld G, Cohen S.

J Biomed Mater Res A. 2003 Jun 15;65(4):489-97.

PMID:
12761840
49.

Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo.

Akiri G, Sabo E, Dafni H, Vadasz Z, Kartvelishvily Y, Gan N, Kessler O, Cohen T, Resnick M, Neeman M, Neufeld G.

Cancer Res. 2003 Apr 1;63(7):1657-66. Erratum in: Cancer Res. 2004 Mar 15;64(6):2306.

50.

The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF.

Neufeld G, Kessler O, Herzog Y.

Adv Exp Med Biol. 2002;515:81-90. Review.

PMID:
12613545

Supplemental Content

Loading ...
Support Center